ACADIA Pharmaceuticals Inc (ACAD) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACADIA Pharmaceuticals Inc (ACAD)

ACAD 21.66

-2.9%

Nov 6 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: tnsaf	4/16/2008 11:17:32 AM
	of 588

9:03AM ACADIA Pharmaceuticals announces primary endpoint of Phase II trial with Pimavanserin is met (ACAD) 7.90 : In a poster presentation titled "A Double-Blind, Placebo-Controlled, Dose-Escalation Trial of Pimavanserin in Parkinson's Disease and Psychosis," ACADIA summarizes data from its double-blind, placebo-controlled Phase II clinical trial that was designed to evaluate the tolerability, safety, and efficacy of pimavanserin in 60 patients with PDP. The primary endpoint of the study was met as pimavanserin did not worsen parkinsonism symptoms that affect activities of daily living and motor function, as measured by the Unified Parkinson's Disease Rating Scale. The use of pimavanserin was shown to be safe and well tolerated. Patients treated with pimavanserin also showed improvements in psychosis scores. The data suggest that pimavanserin, a selective serotonin 5-HT2A inverse agonist that does not block dopamine D2 receptors, may provide antipsychotic benefit to patients with PDP without adversely affecting motor function.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next